FDA sends Merck a Dear John letter on Arcoxia - Apr. 27, 2007: "NEW YORK (CNNMoney.com) -- The FDA shot down Merck's application for an arthritis painkiller that has been widely criticized for its resemblance to Vioxx.
The Food and Drug Administration issued Merck (down $0.78 to $51.65, Charts, Fortune 500) a 'non-approvable letter' for Arcoxia, the drugmaker said on Friday. The letter said Merck needs to provide more test results showing that Arcoxia's benefits outweigh its risks before it has another chance of getting approved."
